exidavnemab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08-17 in 2mo
ESTIMATED |
READOUT
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parki
Phase 2 · Parkinson Disease, Multiple System Atrophy |
BioArctic AB | exidavnemab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|